"We have already seen a similar device that is on the market in the EU have data published in JAMA"
First, we have addressed this before that Toraymyxin's ability to filter entoxins is limited in time due to the fact that only early treatment is usful in this regard. Removal of endotoxins doesn't actively treat the cytokine storm but trying to address the pathogen itself while the organ failure and tissue damage is caused by the immune system itself against the body, not directly from the pathogen.
Second, Endotoxins is limited to bacteria pathogens. Mostly gram-negatives. This limits the treatment especially for viruses that cause the major contributor for sepsis (e.g Pandemic flu, H1N1(swine flu) and so on).
"Most big pharma have exited the device business"
prove this.
"Could the CTSO device be beter? Yes, but that has to be proven and the current study does not even address that question."
what you're saying is very misleading, if the study demonstrates huge difference between control group and treatment group, no one can doubt it. for that there's a p-value too. Generally the medical community seeks treatments that work. if CTSO shows favorable results and the device proved to be effective, market penetration can be easily achieved.
Market Data 
Markets 
AI
